AHA, Merck, Novartis, J&J & CareSet
Venue: Austin Convention Center
Description: New school medical diagnostics and interventions aim to reduce unnecessary procedures, making the procedures that remain far less invasive while ensuring that hard to detect conditions get treatment earlier. The healthcare system needs innovators to make money by lowering costs overall, putting the pressure on traditional inefficient approaches and making space for innovators to shine.
Cat Oyler, Global Head, Strategy & Operations at Johnson & Johnson
Swapnil Rajpathak, Executive Director, Center for Observational and Real World Evidence (CORE) at Merck
David Soergel MD, Global Head, Drug Development Cardiovascular and Metabolic Diseases at Novartis
Patrick Wayte, VP Marketing and Health Education at American Heart Association
Fred Trotter, CareSet (moderator)